SEARCH:   Advanced

Blood, 1 November 2007, Vol. 110, No. 9, pp. 3245-3252. Prepublished online as a Blood First Edition Paper on July 27, 2007; DOI 10.1182/blood-2007-02-072934. This Article Abstract Full Text (PDF) Supplemental Figures All Versions of this Article: blood-2007-02-072934v1 110/9/3245    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lundberg, A. M. Articles by Foxwell, B. M. Search for Related Content PubMed PubMed Citation Articles by Lundberg, A. M. Articles by Foxwell, B. M. Related Collections Immunobiology Signal Transduction Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems Anna M. Lundberg1, Stefan K. Drexler1, Claudia Monaco1, Lynn M. Williams1, Sandra M. Sacre1, Marc Feldmann1, and Brian M. Foxwell1 1 Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College of Science, Technology, and Medicine, London, United Kingdom    Abstract Top Abstract Introduction Materials and methods Results Discussion Authorship References   TLR3 recognizes double-stranded RNA, a product associated with viral infections. Many details of TLR3-induced mechanisms have emerged from gene-targeted mice or inhibition studies in transformed cell lines. However, the pathways activated in human immune cells or cells from disease tissue are less well understood. We have investigated TLR3-induced mechanisms of human primary cells of the innate immune system, including dendritic cells (DCs), macrophages (MØs), endothelial cells (ECs), and synovial fibroblasts isolated from rheumatoid arthritis joint tissue (RA-SFs). Here, we report that while these cells all express TLR3, they differ substantially in their response to TLR3 stimulation. The key antiviral response chemokine IP-10 was produced by all cell types, while DCs and MØs failed to produce the proinflammatory cytokines TNF and IL-6. Unexpectedly, TNF was found secreted by TLR3-stimulated RA-SF. Furthermore, TLR3 stimulation did not activate NFB, MAPKs, or IRF-3 in DCs and MØs, but was able to do so in ECs and RA-SF. These findings were specific for human cells, thereby revealing a complexity not previously expected. This is the first report of such cell type– and species-specific response for any TLR stimulation and helps to explain important difficulties in correlating murine models of inflammatory diseases and human inflammation.    Introduction Top Abstract Introduction Materials and methods Results Discussion Authorship References   The discovery of Toll-like receptors (TLRs) uncovered a key mechanism used by the immune system to detect infections and tissue damage.1 There are 10 known human TLRs that recognize "molecular patterns" produced as a result of pathogenic infections. TLR3 is a member of this receptor family that is activated by double-stranded RNA (dsRNA),2 an intermediate formed by most viruses during their replication. The viral dsRNA functions as a danger signal released in the extracellular environment from dying virally infected cells, alerting inflammatory cells and contributing to systemic disease.3,4 In addition to microbial products, there is growing evidence that TLRs also recognize endogenous ligands found at sites of tissue destruction and cell death,5 and TLR3 has been shown to recognize mRNA released from dying cells.6 Although there are concerns that some of the data on endogenous ligands could be a result of contamination with microbial products, the detection of endogenous ligands would be useful in alerting the host of the presence of tissue injury induced by infection or other means. However, there is a potential drawback in that the same endogenous ligands are also found at sites of chronic inflammation and could further drive the inflammatory response in a TLR-dependent manner. There is increasing evidence that TLRs could be associated with chronic inflammatory diseases such as rheumatoid arthritis (RA).5,7 In this context, TLR3 expression is increased in the RA synovium,8,9 and the presence of TLR3 ligands might affect several aspects of the disease by acting on cells within the joint. In support of this, dsRNA can induce joint inflammation and cause arthritis in a murine disease model.10 Given the importance of TLRs in regulation of both positive and negative aspects of the immune response, there has been much interest in how their activation is controlled. The signaling pathways initiated by most TLRs are regulated by the adaptor protein MyD88 (myeloid differentiation factor 88), with some variations by the additional recruitment of MAL (MyD88 adaptor-like), TRAM (TRIF-related adaptor molecule), and TRIF (TIR-domain–containing adaptor inducing interferon β).11 However, TLR3 is unique since it does not use MyD88 but instead recruits only TRIF, which mediates the activation of NFB and IRF-3. Activation of these pathways results in expression of various inflammatory mediators including the cytokines tumor necrosis factor (TNF) and interleukin-6 (IL-6) and the chemokines IL-8 and IFN-inducible-10 (IP-10). However, as for most TLRs, little is known about TLR3-induced signaling and cellular responses in human primary cells. Previous findings are mainly the result of studies in murine cells, especially derived from knockout animals, or immortalized cell lines, which are all model systems of the human immune system. Furthermore, since many cell lines are of tumor origin, it is unclear if their responses are representative of the normal innate immune response. We therefore felt that it was important to define responses induced by TLR3 in human cell types, and in particular in cells involved in chronic inflammatory disease such as RA. The findings presented here challenge the current beliefs that signaling pathways initiated by the viral response molecule dsRNA are mediated by NFB, MAPK, and IRF-3 in all cell types. Our results highlight that responses induced by dsRNA/TLR3 differ between human cells of separate lineages, as well as between mouse and human. These are crucial findings for increasing the understanding of the human immune system and the inflammatory response to infection.    Materials and methods Top Abstract Introduction Materials and methods Results Discussion Authorship References   Ethical approval for the use of human materials was granted by the Riverside Research Ethics Committee, London, United Kingdom. Reagents Human recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) was generously provided by Beheringwerke (Marburg, Germany) and human recombinant IL-4 was from Novartis Pharma (Basel, Switzerland). Human recombinant macrophage colony-stimulating factor (M-CSF) and human IL-1 were from Genetics Institute (Madison, NJ). Escherichia coli (E coli) LPS was obtained from Sigma (St Louis, MO) and polyinosinic-polycytidylic acid (poly I:C) was from Amersham Life Science (Buckinghamshire, United Kingdom). Mouse serum was purchased from Sigma (St Louis, MO); anti–TLR3-FITC (clone 40C1285.6) (raised against a peptide corresponding to AA 54–71 in the LRR motifs of the TLR3 receptor extracellular domain) was from Imgenex (Cambridge, United Kingdom); and the corresponding IgG1-FITC–labeled isotype control was from Becton Dickinson (Oxford, United Kingdom). Protein inhibitor cocktail and chloroquine were purchased from Sigma (Poole, United Kingdom). The IRF-3 antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA); anti-HA, from Covance (Denver, PA); and anti-Flag, from Sigma (Poole, United Kingdom). Cell isolation and culture conditions Human peripheral blood mononuclear cells were isolated and differentiated for 5 to 7 days with 50 ng/mL GM-CSF, and 10 ng/mL IL-4 for dendritic cells (DCs), and for 3 to 4 days with 100 ng/mL M-CSF for macrophages (MØs), as previously described.12,13 When matured, DCs express the specific marker CD83 and MØs express varied levels of CD14. During assays, both cells were cultured at 106 cells/mL in RPMI1640 5% FCS, 1% penicillin/streptomycin. Rheumatoid arthritis synovial fibroblasts (RA-SFs) and human umbilical vein endothelial cells (HUVECs) were isolated as previously described.14,15 RA-SFs express vimentin at more than 95% and were cultured at 105 cells/mL in DMEM 10% FCS, 100 U/mL penicillin/streptomycin, and 200 µg/mL indomethacin (Sigma, Poole, United Kingdom); HUVECs were 99.19% pure16 and were cultured at 105 cells/mL on gelatin in RPMI1640, 10% FCS, 10% newborn calf serum (Gibco, Auckland, NZ), 1% penicillin/streptomycin, 15 µg/mL endothelial growth supplement (Sigma, Poole, United Kingdom), and 50 IU/mL heparin (CD Pharmaceutical, Wrexham, United Kingdom). Murine bone marrow DCs were derived as previously described17 and cultured at 105 cells/mL in DMEM 5% FCS and 1% penicillin/streptomycin. Reverse transcriptase–polymerase chain reaction RNA was isolated using the Qiagen RNA Blood isolation kit (Qiagen, Hilden, Germany). Total RNA was reverse transcribed with Superscript II RNase H– reverse transcriptase (Gibco, Paisley, United Kingdom) and oligo (dT) primer. The primers used were as follows: 5'-GCAAACACAAGCATTCGGAATCT-3' and 5'-TTGAAGGCTTGGGACCAAGGCA-3' for TLR3; 5'-TGGATACGTTTCCTTATAAG-3' and 5'-GAAATGGAGGCACCCCTTC-3' for TLR4; 5'-GAAGCTCAGAAGCAGTATTGGTC-3' and 5'-GGTTGGTGTAGGATGACAAACTCC-3' for MD-2. Amplification was performed in a Dyad polymerase chain reaction (PCR) machine (MJ Instruments, Watertown, MA) and consisted of 35 cycles with the annealing temperature 62°C for TLR3 and 40 cycles with the annealing temperature 54°C for TLR4 and MD-2. Flow cytometry Intracellular and extracellular TLR3 expressions were determined using flow cytometry. Cells fixed with 2% paraformaldehyde were either left untreated or permeabilized with 1% saponin. The cells were incubated with mouse antihuman TLR3-FITC or isotype control for 30 minutes on ice in the presence of 1% mouse serum. The samples were analyzed on a Becton Dickinson LSR flow cytometer. Cytokine analysis by enzyme-linked immunosorbent assay Supernatants were harvested after 18-hour stimulation with LPS (100 ng/mL) or poly I:C (20 µg/mL). Enzyme-linked immunosorbent assay (ELISA) reagents for measurement of human TNF and IL-6 were from Pharmingen (San Diego, CA) and human IP-10, murine IL-6, and murine TNF reagents were obtained from R&D Systems (Abington, United Kingdom). Absorbance of 450 nm was measured on a spectrophotometric ELISA plate reader (Labsystems Multiscan Biochromic, Cambridge, United Kingdom) using the Ascent version 2.4.2 software program (Thermo Labsystems, Cambridge, United Kingdom). Results are expressed as the mean concentration of triplicate cultures plus or minus SD. Mixed lymphocyte reaction Human DCs were stimulated and cultured in graded doses with 1 x 105 allogeneic elutriated T cells in quadruplicate. Proliferation was measured on day 5 by thymidine incorporation after a 16-hour pulse with [3H] thymidine (0.5 µCi/well [0.0185 MBq]; Amersham Life Science). TaqMan real-time PCR Total RNA was extracted using RNeasy Kit (Qiagen) and PCR was performed using an ABI PRISM 7700 Sequence Detection System and predeveloped assay reagents (PerkinElmer Applied Biosystems, Warrington, United Kingdom). The one-step real-time PCRs were run for 40 cycles, and all quantitations were normalized to GAPDH. Relative quantitation was performed using the comparative Ct method according to the manufacturer's instructions. NFB luciferase reporter assay Cells were infected for 1 to 2 hours in serum-free media with a recombinant replication-deficient adenovirus containing an NFB luciferase reporter gene, which is a modification of the pNFB-Reporter vector (BD Clontech, Palo Alto, CA) and was kindly provided by Dr Paul McCray (University of Iowa). DCs and MØs were infected at 100:1 multiplicity of infection (moi); ECs, at 100:1 at 60% confluence; and RA-SFs, at 500:1, resulting in more than 90% infection efficiencies, as shown by us and others.12,13,18,19 The cells were cultured for 24 hours prior to 6-hour stimulation. The luciferase assay was performed as previously described.20 Western blotting Nuclear protein fractions were extracted as previously described,21 and whole-cell lysates were prepared in 1% Triton X100, 10 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1 mM EDTA, 0.1 mM Na3VO4, 5 mM NaF, 1 mM DTT, and 1 x protein inhibitor cocktail. Equal amounts of proteins were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) on a 10% polyacrylamide gel and transferred to a PVDF membrane for Western blotting. Limulus assay The endotoxin content in all reagents was measured with the Limulus assay (BioWhittaker, Wokingham, United Kingdom) according to the manufacturer's instruction. Only batches of poly I:C with no detectable levels of endotoxin were used in this study. Statistical analyses Mean and standard deviation (SD) were calculated using GraphPad Prism version 3.02 (GraphPad Software, San Diego, CA).    Results Top Abstract Introduction Materials and methods Results Discussion Authorship References   Analysis of TLR3 expression on human immune cells The effects of TLR3 stimulation on human immune cells were analyzed due to their key roles in infectious diseases and acute as well as chronic inflammation. Professional immune cells such as human primary dendritic cells (DCs) and macrophages (MØs), and nonprofessional immune cells such as endothelial cells (ECs) and synovial fibroblasts from RA disease tissue (RA-SFs) were examined. TLR3 expression was detected at the RNA level in all the cell types studied (Figure 1A). By fluorescence-activated cell sorting (FACS), a proportion of the cells was shown to express TLR3 extracellularly, whereas a higher level of TLR3 was found expressed intracellularly in all cell types (Figure 1B). View larger version (42K): [in this window] [in a new window]   Figure 1. TLR3 is expressed on all cell types used in this study. Human DCs were generated from peripheral blood monocytes after 5- to 7-day culture in the presence of 10 ng/mL IL-4 and 50 ng/mL GM-CSF. MØs were differentiated from peripheral blood monocytes for 3 to 4 days in the presence of 100 ng/mL M-CSF. ECs were isolated from human umbilical veins and were used at passages 2 to 3. Fibroblasts were isolated from synovial tissue from RA patients undergoing joint replacement. (A) Total RNA was isolated from each cell type and 1 µg was subjected to reverse transcriptase-PCR and analyzed for TLR3, TLR4, MD-2, or GAPDH expression with PCR. – indicates PCR-negative control. (B) DCs, MØs, ECs, and RA-SFs were analyzed for both intracellular and membrane-bound TLR3 by flow cytometry. Cells stained with isotype control (filled histograms) or anti–TLR3-FITC antibody (open black histograms) are shown.   Differential induction of proinflammatory and interferon response cytokines by TLR3 stimulation To evaluate the responses of TLR3 stimulation, the effects of poly I:C treatment on cytokine production by the different human immune cells were examined. The TLR4 ligand LPS was used as a control stimulus, and, as shown in Figure 1A, all cell types studied also express TLR4 and MD-2. In murine cells, LPS induces similar pathways as dsRNA, leading to production of proinflammatory cytokines such as IL-6 and TNF, as well as expression of IFN-regulated genes (IRGs), such as the chemokine IP-10.2,22 As predicted, poly I:C induced IP-10 production from DCs to similar levels as LPS-stimulated cells (Figure 2A). However unlike LPS, poly I:C did not induce TNF, IL-6 (Figure 2A), or IL-8 (data not shown) in human DCs. This was not due to production of the anti-inflammatory cytokine IL-10, since it was not induced by poly I:C, whereas IL-10 was produced after LPS stimulation (Figure S1, available on the Blood website; see the Supplemental Materials link at the top of the online article). The induction of IP-10 but not TNF or IL-6 was repeated in poly I:C–stimulated MØs (Figure 2A). This effect was specific for human cells, since TNF or IL-6 was produced by murine DCs after poly I:C stimulation (Figure 2B), confirming previous studies.2,22 As poly I:C was described by another group to induce TNF and IL-6 mRNA in human DCs,23 we investigated whether stimulation with poly I:C could increase TNF and IL-6 mRNA levels in the absence of increased protein expression. However, studies of mRNA expression confirmed our protein studies with poly I:C inducing very little, if any, TNF and IL-6 mRNA, whereas LPS caused high mRNA levels of both cytokines (Figure 2C). In addition, we could detect type I IFN from both poly I:C– and LPS-stimulated human DCs (data not shown). Stimulation of human DCs with poly I:C was also previously shown to induce DC activation and functional maturation.24–26 We could confirm these findings, since poly I:C stimulation of human DCs resulted in increased ability to induce an allogenic MLR (Figure 2D) and up-regulation of the costimulatory markers CD80 and CD86 and the maturation markers HLA-DR and CD83 (Figure 2D). View larger version (33K): [in this window] [in a new window]   Figure 2. Poly I:C–induced expression of IFN-regulated genes but not proinflammatory cytokines is both cell-type and species specific. (A) Human DCs and MØs, (B) murine DCs, (E) ECs, and (E,F) RA-SFs were stimulated with either 100 ng/mL LPS or poly I:C (in µg/mL) as indicated. The supernatants were analyzed for IP-10, IL-6, and TNF by ELISA. The data are mean values (± SD) from triplicates and are representative of at least 3 experiments using cells of different donors. (C) Human DCs were stimulated with either 100 ng/mL LPS or 20 µg/mL poly I:C, and total RNA was isolated and assessed for the levels of TNF and IL-6 mRNA by Taqman PCR. The points correspond to values from 4 different donors (± SD). (D) Human DCs were stimulated with 20 µg/mL poly I:C or 100 ng/mL LPS and cocultured with 105 allogeneic T cells in quadruplicate. Proliferation was determined on day 5 using [3H] thymidine. Each point represents the mean (± SEM) from 3 independent experiments on unrelated donors. Human DCs were also examined for cell surface expression of CD80, CD86, HLA-DR, and CD83 by flow cytometry. Unstimulated DCs (black line) and DCs treated with 20 µg/mL poly I:C for 48 hours (gray line) were compared. Cells stained with isotype control (filled histograms) or anti-TLR3 antibody (open black histograms) are shown. One representative of 3 independent experiments is shown.   Given these unexpected findings in human primary DCs and MØs, we examined the responses to poly I:C in ECs, which was previously shown to produce IL-6 mRNA and adhesion molecules after poly I:C stimulation.27,28 In addition, we analyzed the responses in RA-SFs, which have also been shown to respond to poly I:C treatment.29–31 Stimulation of ECs with poly I:C induced IP-10 secretion, whereas no substantial production could be observed after LPS treatment (Figure 2E). Furthermore, poly I:C stimulation of ECs led to the production of IL-6 and IL-8, at levels comparable with LPS (Figure 2E and data not shown). Similar results were also observed for poly I:C–stimulated RA-SFs (Figure 2E). An interesting observation made in this study was that poly I:C could induce TNF secretion by human RA-SFs (Figure 2F). This effect was specific to poly I:C since TNF levels could not be detected after LPS stimulation (Figure 2F). It was also found specific for RA-SF, since poly I:C–stimulated human skin fibroblasts (HSFs) produced only IL-6 and not TNF (data not shown). This is the first report describing the ability of a ligand to induce TNF production from a human fibroblast population. Overall, these results indicated that responses induced by poly I:C in human cells differed depending on the cell lineage and can be divided into response induced by myeloid cells (DCs and MØs) and nonmyeloid cells (ECs and RA-SFs). Poly I:C stimulation was previously shown to be blocked by inhibitors of endosomal maturation,32,33 suggesting that the TLR3 signaling is initiated intracellularly. To address this issue, we investigated if the cell type–specific difference was the result of TLR3 activation mediated from different locations in myeloid and nonmyeloid cells. However, in the presence of chloroquine, an inhibitor of endosomal acidification, IP-10 production was inhibited in both DCs and RA-SFs (Figure 3). This suggests that cells of both lineages use the intracellular TLR3 and that the distribution of the receptor is not the cause of these variations. View larger version (19K): [in this window] [in a new window]   Figure 3. Poly I:C stimulation is dependent on endosomal maturation in both human dendritic cells and RA synovial fibroblasts. Human DCs and RA-SFs were incubated with chloroquine for 1 hour prior to stimulation with 20 µg/mL poly I:C for 18 hours. The supernatants were analyzed by ELISA. The data are mean values (± SD) from triplicates.   Cell lineage–specific activation of NFB and MAPKs upon TLR3 stimulation The finding that poly I:C induces only proinflammatory cytokines in certain cell types prompted the examination of downstream signaling pathways. NFB is involved in regulating TNF and IL-6 expression, and previous studies have claimed that dsRNA stimulation can activate NFB.2,34–39 We examined if the cell type–specific differences observed with cytokine production were due to a variation in NFB regulation. Interestingly, in DCs and MØs, poly I:C was unable to activate NFB, whereas LPS was a potent activator, as expected (Figure 4A). In contrast, NFB transcriptional activity in ECs and RA-SFs was induced by poly I:C to levels comparable with LPS stimulation (Figure 4A). Furthermore, the lack of response in the myeloid cells was again shown to be a species-specific effect of human cells since poly I:C could stimulate NFB activity in murine DCs (Figure 4B). The NFB results were supported by studies of poly I:C–induced IB degradation. In a similar manner, poly I:C did not induce IB degradation in either DCs (Figure 5A) or MØs (data not shown). Conversely, poly I:C stimulation of RA-SFs resulted in IB degradation, confirming our NFB results (Figure 5B). The poly I:C–induced IB degradation in RA-SFs occurred with a delayed kinetics than LPS stimulation, which induced IB degradation in all cell types, as expected. View larger version (21K): [in this window] [in a new window]   Figure 4. Poly I:C stimulation induces activation of NFB in endothelial cells and RA synovial fibroblasts but not in dendritic cells and macrophages. (A) Human DCs, MØs, ECs, RA-SFs, and (B) murine DCs were infected for 1 hour with an adenovirus carrying an NFB luciferase reporter gene. The cells were stimulated for 6 hours with 100 ng/mL LPS or poly I:C (in µg/mL) as indicated and then analyzed for luciferase activity. The data are mean values (± SD) from triplicates and are representative of at least 3 experiments using cells of different donors.   View larger version (43K): [in this window] [in a new window]   Figure 5. Poly I:C stimulation induces degradation of IB in fibroblasts but not in dendritic cells. (A) DCs and (B) RA-SFs were either left untreated (Un) or stimulated with poly I:C (20µg/mL) or LPS (100 ng/mL). The cell lysates were examined for the level of IB, β-actin, or -tubulin by Western blotting. Representatives of 3 independent experiments per cell type are shown.   The production of proinflammatory cytokines can also be regulated by the 3 major MAPKs: p38 MAPK, JNK (p46/p54), and ERK (p42/p44) MAPKs. It was previously reported that poly I:C treatment induced phosphorylation of the MAPKs in murine cells and various cell lines.2,35,36,40–44 However in our study, poly I:C stimulation did not induce phosphorylation of p38, JNKs, or ERKs at any time point analyzed in either human DCs (Figure 6A) or MØs (data not shown), whereas LPS was found to potently induce all 3 groups of MAPKs, as expected. Conversely, stimulation of RA-SFs by both poly I:C and LPS resulted in activation of all 3 MAPKs, albeit with different kinetics (Figure 6B). To elucidate if the late activation of the MAPK in response to poly I:C was due to an indirect effect, we stimulated RA-SFs in the presence of brefeldin A, an inhibitor of the secretory pathway. Brefeldin A had no effect on poly I:C–induced ERK phosphorylation (Figure S2), indicating that the activation was not mediated by a secreted autocrine mediator. View larger version (32K): [in this window] [in a new window]   Figure 6. Poly I:C treatment does not induce phosphorylation of p38, JNK, and ERK in human dendritic cells but does so in RA synovial fibroblasts. (A) Human DCs and (B) synovial fibroblasts from RA tissue were either left untreated (Un) or stimulated with LPS (100 ng/mL) or poly I:C (20µg/mL). The cell lysates were examined for phospho-p38, phospho-JNK, phospho-ERK, or β-actin by Western blotting. Representatives of 3 independent experiments are shown.   IRF-3 activation in response to poly I:C stimulation is restricted to cells of nonmyeloid lineage IRF-3 has been shown to have a critical role in TLR3-induced responses through the TRIF-dependent pathway leading to IFNs and IRGs, such as IP-10. We aimed to address the question of whether the induction of IRF-3 could explain the poly I:C–induced IP-10 production in DCs and MØs in the absence of NFB and MAPK activation. IRF-3 is found in the cytoplasm as an inactive monomer and becomes activated by phosphorylation, followed by dimerization and translocation to the nucleus.45,46 The involvement of IRF-3 in poly I:C signaling was examined by measuring the change in IRF-3 nuclear levels. In this study, we could only detect IRF-3 nuclear translocation after LPS, but not poly I:C treatment of DCs (Figure 7A) and MØs (data not shown). Conversely, in both RA-SFs (Figure 7B) and ECs (data not shown), the results showed enhanced levels of nuclear IRF-3 after only poly I:C and not LPS stimulation. These results further confirmed that signaling events induced by poly I:C are tightly regulated according to the cell type involved, and differ substantially between professional and nonprofessional immune cells. View larger version (64K): [in this window] [in a new window]   Figure 7. Poly I:C stimulation of RA synovial fibroblasts but not DCs activates nuclear translocation of IRF-3. (A) Human DCs and (B) RA-SFs were either left unstimulated (Un) or stimulated with poly I:C (20 µg/mL) and LPS (100 ng/mL), and the nuclear fractions were examined for nuclear IRF-3 and topoisomerase by Western blotting. Representatives of 3 independent experiments per cell type are shown.      Discussion Top Abstract Introduction Materials and methods Results Discussion Authorship References   This study investigated and compared the responses induced by TLR3 stimulation of human primary DCs, MØs, ECs, and RA-SFs from disease tissue. These cell types are involved in responses to infection and both acute and chronic inflammation. The results in this study have uncovered a considerable selectivity in the TLR3-induced responses of these cell types, with substantial differences observed between myeloid cells (DCs and MØs) and nonmyeloid cells (ECs and RA-SFs). Surprisingly, DCs and MØs were found to produce the IRG IP-10, but not cytokines such as TNF, IL-6, or IL-8 after poly I:C stimulation. Studies on mRNA expression of TNF and IL-6 in human DCs confirmed our protein data showing no poly I:C–induced cytokine production, whereas we could detect IFNβ mRNA, as shown by other groups.25,26 This contradicts a previously published study that failed to detect IFNβ but showed induction of TNF and IL-6 mRNA, although no protein studies were performed.23 Furthermore, we showed that poly I:C stimulation of human DCs induced up-regulation of the maturation markers HLA-DR, CD80, CD86, and CD83, and T-cell stimulatory capacity, all of which have previously been demonstrated by other groups.24–26 This is the first report showing induction of DC maturation and production of IRGs from human DCs and MØs, but not proinflammatory cytokines, in response to TLR3 stimulation. Furthermore, of great interest, this phenotype was shown to be specific for human myeloid cells since both TNF and IL-6 could be produced by murine DCs after poly I:C stimulation. Moreover, in contrast to DCs and MØs, the cells of nonmyeloid origin, ECs and RA-SFs, produced both types of cytokines after poly I:C treatment. This is a major difference in the behavior of TLR3 signaling between human and mouse and could affect how we interpret and extrapolate data between the 2 systems, especially when considering viral disease models, where TLR3 might have a role, or where cell necrosis and release of RNA may be involved. The differences between the myeloid and nonmyeloid cell types were also reflected in the TLR3 signaling pathways. Unexpectedly, poly I:C did not induce activation of NFB, MAPKs, or IRF3 in DCs and MØs, but was able to do so in ECs and RA-SFs. The inability of poly I:C to activate these pathways in DCs and MØs could explain the failure to produce TNF, IL-6, and IL-8, since their expressions are regulated by NFB. Conversely, the activation of NFB and MAPKs in RA-SFs and ECs would also explain why poly I:C could induce IL-6 and IL-8 in these cells. Our results confirm the previously reported observation that poly I:C stimulation regulates NFB in human ECs.27,47 We have previously shown that there are major differences in the signaling pathways of other TLRs between human cells of myeloid and nonmyeloid lineages.19,20,48 A possible explanation for our results could be cell type–specific expression of signaling molecules between cell lineages, as was shown with IKK expression between murine macrophages and fibroblasts.49 Such differential expression could account for IFNβ and IP-10 production but no NFB activation or secretion of proinflammatory cytokines in poly I:C–stimulated DCs and MØs. It is possible that these cells lack a signaling molecule similar to feckless described by Beutler et al.50 Cells from mice with a feckless mutation fail to activate NFB or produce TNF in response to dsRNA/TLR3, although dsRNA is still able to initiate IFNβ production. Another possibility is that additional transcription factors, such as other IRFs, are involved in TLR3 activation in human myeloid cells. As such, we have evidence that poly I:C induces a rapid and transient nuclear accumulation of IRF-1 in DCs (Figure S3). This is an interesting area that we are actively pursuing further. An interesting finding in this study was that poly I:C stimulation of RA-SFs induced TNF production, which was specific for poly I:C since LPS treatment failed to induce the same response. The ability of poly I:C to induce TNF production does not appear to be a general property of all fibroblast populations. We were unable to detect TNF production in HSFs in response to poly I:C even though IL-6 was produced by these cells. This is not the only difference we have observed between RA-SFs and HSFs, as the former48 unlike the latter are able to respond to LPS. One could therefore hypothesize that RA-SFs have an inflammatory phenotype, possibly due to their environment. It is interesting to note that poly I:C induces TNF production in cultures of RA joint synovial membranes from which RA-SFs are derived (S.M.S. et al, manuscript in preparation). Furthermore, TNF production by poly I:C–stimulated RA-SFs is unlikely to be caused by contamination of MØs or T cells, since we could not detect CD14- or CD3-expressing cells in our RA-SF cultures. If MØs were present, we would have observed TNF expression after LPS and not poly I:C stimulation of these cultures. However, although unlikely, we cannot completely rule out the presence of other contaminating cell types. Historically nonmyeloid cells were not believed to be able to express TNF, however, supporting observations were recently reported by 2 independent groups in murine embryonic fibroblasts (MEFs).51,52 They showed that LPS stimulation of MEFs induced low levels of TNF that was a result of IRF-3 activation. We show in our human cell systems that there is a correlation between TNF production and IRF-3 activation. As such, LPS stimulation of DCs and MØs induces TNF production and IRF-3 activation, whereas poly I:C does not. The situation is reversed in RA-SFs and it is poly I:C stimulation and not LPS that induces both TNF and IRF-3. We have previously shown that NFB is required for LPS-induced MHC class II and CD80/86 expression and antigen presentation.53,54 However, since TLR3-induced up-regulation of these molecules could be observed in the absence of a detectable NFB activation, their expression appears to be NFB independent. Furthermore, IRF-3 is thought to be required for TLR3-induced type I IFN and IP-10 production. However, since no IRF-3 activation could be seen in DCs and MØs, it is unclear what regulates the production of IP-10 and type I IFNs in these cell types. This is the subject of ongoing investigations. One obvious reason for the variations between the cell types is that they have very different functions in the immune system. DCs and MØs are professional antigen-presenting cells involved in T-cell activation, whereas ECs and RA-SFs are nonprofessional immune cells. Thus, given their diverse roles in the immune response, it makes sense that the same ligand would induce individual cell type–specific responses. For example, stimulation of DCs and MØs by TLR3 appeared to selectively induce IP-10, a key chemokine targeting T lymphocytes, hence specifically enhancing recruitment of T cells to the site of inflammation. In contrast, this selectivity in cytokine production was not observed with ECs and RA-SFs. In these cells, TLR3 activation instead induced a broader range of proinflammatory mediators, suggesting participation of these cell types to chronic inflammation. We also show that TLR3 stimulation results in DC maturation, favoring increased T-cell activation. Furthermore, DCs and MØs are capable of inducing cross-presentation,55,56 and TLR3-stimulated DCs can cross-present antigens from virally infected cells to promote priming of virus-specific T cells.57–59 It is therefore possible that TLR3-stimulated DCs and MØs are involved in recruitment of T cells and induction of cross-presentation. Interestingly, TLR3 stimulation also leads to a marked increase in cross-priming toward cell-associated antigens.60 In this way, peripheral tolerance could be overcome by dsRNA and thus trigger an autoimmune organ-specific disease.60 The results presented in this study differ from the literature using other cell systems, and they indicate that the signaling pathways induced by poly I:C in human primary cell types and cells from disease tissue are complex. While these observations have raised the question of why differences exist between cell types stimulated with the same ligand, they also highlight the importance of studying signaling pathways in relevant cell types and the danger in directly transferring the results observed in cell lines or murine systems to human systems. By characterizing the pattern of activation induced by each cell type in response to the TLR3 ligand, this study increases the understanding of the possible contributions of each cell to the innate host responses to viral infections or tissue damage. The differences in TLR3 stimulation between the cell types are subject to further investigation, in order to fully understand the specific role of TLR3 in the human immune response.    Authorship Top Abstract Introduction Materials and methods Results Discussion Authorship References   Contribution: A.M.L. and S.K.D. performed research; C.M., L.M.W., and S.M.S. contributed new reagents/analytic tools; A.M.L, M.F., and B.M.F. designed research, analyzed data, and wrote the paper. B.M.F. and M.F. contributed equally to this work. Conflict-of-interest disclosure: The authors declare no competing financial interests. Correspondence: Brian M. Foxwell, Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College of Science, Technology and Medicine, 1 Aspenlea Road, Hammersmith, London, W6 8LH, United Kingdom; e-mail: b.foxwell{at}imperial.ac.uk.    Acknowledgments   This work was supported by grants from the Arthritis Research Campaign of the United Kingdom and the Kennedy Institute of Rheumatology Trustees.    Footnotes   Submitted February 7, 2007; accepted July 19, 2007. Prepublished online as Blood First Edition Paper, July 27, 2007 DOI: 10.1182/blood-2007-02-072934 The online version of this article contains a data supplement. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.    References Top Abstract Introduction Materials and methods Results Discussion Authorship References   Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783–801.[CrossRef][Medline] [Order article via Infotrieve] Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732–738.[CrossRef][Medline] [Order article via Infotrieve] Majde JA, Guha-Thakurta N, Chen Z, Bredow S, Krueger JM. Spontaneous release of stable viral double-stranded RNA into the extracellular medium by influenza virus-infected MDCK epithelial cells: implications for the viral acute phase response. Arch Virol 1998; 143:2371–2380.[CrossRef][Medline] [Order article via Infotrieve] Majde JA, Brown RK, Jones MW, et al. Detection of toxic viral-associated double-stranded RNA (dsRNA) in influenza-infected lung. Microb Pathog 1991; 10:105–115.[CrossRef][Medline] [Order article via Infotrieve] Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6:823–835.[CrossRef][Medline] [Order article via Infotrieve] Kariko K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004; 279:12542–12550.[Abstract/Free Full Text] Andreakos E, Foxwell B, Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev 2004; 202:250–265.[CrossRef][Medline] [Order article via Infotrieve] Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 2005; 52:2656–2665.[CrossRef][Medline] [Order article via Infotrieve] Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, et al. The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum 2005; 52:2313–2322.[CrossRef][Medline] [Order article via Infotrieve] Zare F, Bokarewa M, Nenonen N, et al. Arthritogenic properties of double-stranded (viral) RNA. J Immunol 2004; 172:5656–5663.[Abstract/Free Full Text] Takeda K and Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17:1–14.[Abstract/Free Full Text] Andreakos E, Smith C, Monaco C, Brennan FM, Foxwell BM, Feldmann M. Ikappa B kinase 2 but not NF-kappa B-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction. Blood 2003; 101:983–991.[Abstract/Free Full Text] Foxwell B, Browne K, Bondeson J, et al. Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc Natl Acad Sci U S A 1998; 95:8211–8215.[Abstract/Free Full Text] Butler DM, Feldmann M, Di Padova F, Brennan FM. p55 and p75 tumor necrosis factor receptors are expressed and mediate common functions in synovial fibroblasts and other fibroblasts. Eur Cytokine Netw 1994; 5:441–448.[Medline] [Order article via Infotrieve] Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52:2745–2756.[Medline] [Order article via Infotrieve] Paleolog EM, Aluri GR, Feldmann M. Contrasting effects of interferon gamma and interleukin 4 on responses of human vascular endothelial cells to tumour necrosis factor alpha. Cytokine 1992; 4:470–478.[CrossRef][Medline] [Order article via Infotrieve] James E, Scott D, Chai JG, Millrain M, Chandler P, Simpson E. HY peptides modulate transplantation responses to skin allografts. Int Immunol 2002; 14:1333–1342.[Abstract/Free Full Text] Wrighton CJ, Hofer-Warbinek R, Moll T, Eytner R, Bach FH, de Martin R. Inhibition of endothelial cell activation by adenovirus-mediated expression of I kappa B alpha, an inhibitor of the transcription factor NF-kappa B. J Exp Med 1996; 183:1013–1022.[Abstract/Free Full Text] Smith C, Andreakos E, Crawley JB, Brennan FM, Feldmann M, Foxwell BM. NF-kappaB-inducing kinase is dispensable for activation of NF-kappaB in inflammatory settings but essential for lymphotoxin beta receptor activation of NF-kappaB in primary human fibroblasts. J Immunol 2001; 167:5895–5903.[Abstract/Free Full Text] Sacre SM, Lundberg AM, Andreakos E, Taylor C, Feldmann M, Foxwell BM. Selective use of TRAM in lipopolysaccharide (LPS) and lipoteichoic acid (LTA) induced NF-kappaB activation and cytokine production in primary human cells: TRAM is an adaptor for LPS and LTA signaling. J Immunol 2007; 178:2148–2154.[Abstract/Free Full Text] Whiteside ST, Visvanathan KV, Goodbourn S. Identification of novel factors that bind to the PRD I region of the human beta-interferon promoter. Nucleic Acids Res 1992; 20:1531–1538.[Abstract/Free Full Text] Doyle S, Vaidya S, O'Connell R, et al. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity 2002; 17:251–263.[CrossRef][Medline] [Order article via Infotrieve] Re F and Strominger JL. IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells. J Immunol 2004; 173:7548–7555.[Abstract/Free Full Text] Verdijk RM, Mutis T, Esendam B, et al. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol 1999; 163:57–61.[Abstract/Free Full Text] Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med 1999; 189:821–829.[Abstract/Free Full Text] Vidalain PO, Azocar O, Yagita H, Rabourdin-Combe C, Servet-Delprat C. Cytotoxic activity of human dendritic cells is differentially regulated by double-stranded RNA and CD40 ligand. J Immunol 2001; 167:3765–3772.[Abstract/Free Full Text] Offermann MK, Zimring J, Mellits KH, et al. Activation of the double-stranded-RNA-activated protein kinase and induction of vascular cell adhesion molecule-1 by poly (I). poly (C) in endothelial cells. Eur J Biochem 1995; 232:28–36.[Medline] [Order article via Infotrieve] Harcourt JL, Hagan MK, Offermann MK. Modulation of double-stranded RNA-mediated gene induction by interferon in human umbilical vein endothelial cells. J Interferon Cytokine Res 2000; 20:1007–1013.[CrossRef][Medline] [Order article via Infotrieve] Yaron M, Yaron I, Smetana O, Eylan E, Herzberg M. Hyaluronic acid produced by human synovial fibroblasts: effect of polyinosinic-polycytidylic acid (poly I:C) and interferon. Arthritis Rheum 1976; 19:1315–1320.[CrossRef][Medline] [Order article via Infotrieve] Yaron M, Yaron I, Wiletzki C, Zor U. Interrelationship between stimulation of prostaglandin E and hyaluronate production by poly (I). poly (C) and interferon in synovial fibroblast culture. Arthritis Rheum 1978; 21:694–698.[Medline] [Order article via Infotrieve] Meyer FA, Yaron I, Yaron M. Stimulation of collagenase production in human synovial fibroblast cultures by poly (I). poly (C). J Rheumatol 1987; 14:429–434.[Medline] [Order article via Infotrieve] Matsumoto M, Funami K, Tanabe M, et al. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 2003; 171:3154–3162.[Abstract/Free Full Text] de Bouteiller O, Merck E, Hasan UA, et al. Recognition of double-stranded RNA by human toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J Biol Chem 2005; 280:38133–38145.[Abstract/Free Full Text] Visvanathan KV and Goodbourn S. Double-stranded RNA activates binding of NF-kappa B to an inducible element in the human beta-interferon promoter. EMBO J 1989; 8:1129–1138.[Medline] [Order article via Infotrieve] Chu WM, Ostertag D, Li ZW, et al. JNK2 and IKKbeta are required for activating the innate response to viral infection. Immunity 1999; 11:721–731.[CrossRef][Medline] [Order article via Infotrieve] Jiang Z, Zamanian-Daryoush M, Nie H, Silva AM, Williams BR, Li X. Poly(I-C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFkappa B and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR. J Biol Chem 2003; 278:16713–16719.[Abstract/Free Full Text] Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003; 301:640–643.[Abstract/Free Full Text] Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat Immunol 2003; 4:161–167.[CrossRef][Medline] [Order article via Infotrieve] Jiang Z, Mak TW, Sen G, Li X. Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proc Natl Acad Sci U S A 2004; 101:3533–3538.[Abstract/Free Full Text] Goh KC, deVeer MJ, Williams BR. The protein kinase PKR is required for p38 MAPK activation and the innate immune response to bacterial endotoxin. EMBO J 2000; 19:4292–4297.[CrossRef][Medline] [Order article via Infotrieve] Maggi LB Jr, Moran JM, Buller RM, Corbett JA. ERK activation is required for double-stranded RNA- and virus-induced interleukin-1 expression by macrophages. J Biol Chem 2003; 278:16683–16689.[Abstract/Free Full Text] Meusel TR and Imani F. Viral induction of inflammatory cytokines in human epithelial cells follows a p38 mitogen-activated protein kinase-dependent but NF-kappa B-independent pathway. J Immunol 2003; 171:3768–3774.[Abstract/Free Full Text] Pisegna S, Pirozzi G, Piccoli M, Frati L, Santoni A, Palmieri G. p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells. Blood 2004; 104:4157–4164.[Abstract/Free Full Text] Steer SA, Moran JM, Christmann BS, Maggi LB Jr, Corbett JA. Role of MAPK in the regulation of double-stranded RNA- and encephalomyocarditis virus-induced cyclooxygenase-2 expression by macrophages. J Immunol 2006; 177:3413–3420.[Abstract/Free Full Text] Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujita T. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J 1998; 17:1087–1095.[CrossRef][Medline] [Order article via Infotrieve] Suhara W, Yoneyama M, Iwamura T, et al. Analyses of virus-induced homomeric and heteromeric protein associations between IRF-3 and coactivator CBP/p300. J Biochem (Tokyo) 2000; 128:301–307.[Abstract/Free Full Text] Kaiser WJ, Kaufman JL, Offermann MK. IFN-alpha sensitizes human umbilical vein endothelial cells to apoptosis induced by double-stranded RNA. J Immunol 2004; 172:1699–1710.[Abstract/Free Full Text] Andreakos E, Sacre SM, Smith C, et al. Distinct pathways of LPS-induced NF-kappa B activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP. Blood 2004; 103:2229–2237.[Abstract/Free Full Text] Perry AK, Chow EK, Goodnough JB, Yeh WC, Cheng G. Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection. J Exp Med 2004; 199:1651–1658.[Abstract/Free Full Text] Beutler B, Jiang Z, Georgel P, et al. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu Rev Immunol 2006; 24:353–389.[CrossRef][Medline] [Order article via Infotrieve] Covert MW, Leung TH, Gaston JE, Baltimore D. Achieving stability of lipopolysaccharide-induced NF-kappaB activation. Science 2005; 309:1854–1857.[Abstract/Free Full Text] Werner SL, Barken D, Hoffmann A. Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science 2005; 309:1857–1861.[Abstract/Free Full Text] Yoshimura S, Bondeson J, Foxwell BM, Brennan FM, Feldmann M. Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines. Int Immunol 2001; 13:675–683.[Abstract/Free Full Text] Yoshimura S, Bondeson J, Brennan FM, Foxwell BM, Feldmann M. Role of NFkappaB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI. Eur J Immunol 2001; 31:1883–1893.[CrossRef][Medline] [Order article via Infotrieve] Rock KL and Shen L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev 2005; 207:166–183.[CrossRef][Medline] [Order article via Infotrieve] Ramirez MC and Sigal LJ. Macrophages and dendritic cells use the cytosolic pathway to rapidly cross-present antigen from live, vaccinia-infected cells. J Immunol 2002; 169:6733–6742.[Abstract/Free Full Text] Datta SK, Redecke V, Prilliman KR, et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol 2003; 170:4102–4110.[Abstract/Free Full Text] Fujimoto C, Nakagawa Y, Ohara K, Takahashi H. Polyriboinosinic polyribocytidylic acid [poly(I:C)]/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes. Int Immunol 2004; 16:55–63.[Abstract/Free Full Text] Schulz O, Diebold SS, Chen M, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005; 433:887–892.[CrossRef][Medline] [Order article via Infotrieve] Lang KS, Recher M, Junt T, et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 2005; 11:138–145.[CrossRef][Medline] [Order article via Infotrieve] CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: G. Jiang, Y. Ke, D. Sun, Y. Wang, H. J. Kaplan, and H. Shao Regulatory Role of TLR Ligands on the Activation of Autoreactive T Cells by Retinal Astrocytes Invest. Ophthalmol. Vis. Sci., October 1, 2009; 50(10): 4769 - 4776. [Abstract] [Full Text] [PDF] C. K. Holm, C. C. Petersen, M. Hvid, L. Petersen, S. R. Paludan, B. Deleuran, and M. Hokland TLR3 Ligand Polyinosinic:Polycytidylic Acid Induces IL-17A and IL-21 Synthesis in Human Th Cells J. Immunol., October 1, 2009; 183(7): 4422 - 4431. [Abstract] [Full Text] [PDF] W. G. Cho, R. J. C. Albuquerque, M. E. Kleinman, V. Tarallo, A. Greco, M. Nozaki, M. G. Green, J. Z. Baffi, B. K. Ambati, M. De Falco, et al. Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth PNAS, April 28, 2009; 106(17): 7137 - 7142. [Abstract] [Full Text] [PDF] R. E. Simmonds, F. V. Lali, T. Smallie, P. L. C. Small, and B. M. Foxwell Mycolactone Inhibits Monocyte Cytokine Production by a Posttranscriptional Mechanism J. Immunol., February 15, 2009; 182(4): 2194 - 2202. [Abstract] [Full Text] [PDF] M Corr, D L Boyle, L Ronacher, N Flores, and G S Firestein Synergistic benefit in inflammatory arthritis by targeting I{kappa}B kinase {epsilon} and interferon {beta} Ann Rheum Dis, February 1, 2009; 68(2): 257 - 263. [Abstract] [Full Text] [PDF] A. Shibamiya, K. Hersemeyer, T. Schmidt Woll, D. Sedding, J.-M. Daniel, S. Bauer, T. Koyama, K. T. Preissner, and S. M. Kanse A key role for Toll-like receptor-3 in disrupting the hemostasis balance on endothelial cells Blood, January 15, 2009; 113(3): 714 - 722. [Abstract] [Full Text] [PDF] S. M. Sacre, A. Lo, B. Gregory, R. E. Simmonds, L. Williams, M. Feldmann, F. M. Brennan, and B. M. Foxwell Inhibitors of TLR8 Reduce TNF Production from Human Rheumatoid Synovial Membrane Cultures J. Immunol., December 1, 2008; 181(11): 8002 - 8009. [Abstract] [Full Text] [PDF] T. Yoshizawa, D. Hammaker, S. E. Sweeney, D. L. Boyle, and G. S. Firestein Synoviocyte Innate Immune Responses: I. Differential Regulation of Interferon Responses and the JNK Pathway by MAPK Kinases J. Immunol., September 1, 2008; 181(5): 3252 - 3258. [Abstract] [Full Text] [PDF] T. Reimer, M. Brcic, M. Schweizer, and T. W. Jungi poly(I:C) and LPS induce distinct IRF3 and NF-{kappa}B signaling during type-I IFN and TNF responses in human macrophages J. Leukoc. Biol., May 1, 2008; 83(5): 1249 - 1257. [Abstract] [Full Text] [PDF] R. E. Simmonds and B. M. Foxwell Signalling, inflammation and arthritis: NF-{kappa}B and its relevance to arthritis and inflammation Rheumatology, May 1, 2008; 47(5): 584 - 590. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Supplemental Figures All Versions of this Article: blood-2007-02-072934v1 110/9/3245    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lundberg, A. M. Articles by Foxwell, B. M. Search for Related Content PubMed PubMed Citation Articles by Lundberg, A. M. Articles by Foxwell, B. M. Related Collections Immunobiology Signal Transduction Social Bookmarking                   What's this?

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020